Sentences with phrase «immunotherapy pembrolizumab»

The immunotherapy pembrolizumab was active in patients with advanced mucosal melanoma enrolled in a series of the KEYNOTE clinical trials, according to data presented at the European Cancer Congress 2017.

One patient was treated with the immunotherapy pembrolizumab and now more than a year after starting treatment remains on the drug with 77 percent tumor reduction and no new metastases.

Not exact matches

Pembrolizumab, or pembro, an immunotherapy drug that unmasks cancer cells and allows the body's own immune system to help destroy tumors, appears to be safe in treating lung cancers, according to a study by Cancer Treatment Centers of America ® (CTCA) at Western Regional Medical Center (Western) in Goodyear, Arizona.

In a phase 1b clinical trial with 21 patients, researchers tested the safety and efficacy of combining the immunotherapy drug pembrolizumab with an oncolytic virus called T - VEC.

The immunotherapy drug pembrolizumab — already FDA - approved for other forms of cancer - has been found to be effective in patients with metastatic triple negative breast cancer, according to an international clinical trial led by NYU Langone's Perlmutter Cancer Center.

«Immunotherapy drug effective for metastatic triple negative breast cancer: Pembrolizumab shown to shrink tumors — regardless of whether patient had prior treatment.»

Clinical trials of a new immunotherapy, pembrolizumab, have shown that it prolongs life significantly for patients with bladder cancer and is active against a rare sub-type of melanoma, called mucosal melanoma.

«Immunotherapy, pembrolizumab, is active against mucosal melanoma tumors: And prolongs survival for patients with bladder cancer.»

Once they identified this pathway, Hanks and colleagues conducted laboratory tests of a molecule that blocks melanoma cells from going stealth, enabling the immune system to mount a direct attack while also enhancing the function of current immunotherapies such as pembrolizumab and nivolumab.

The immunotherapy drug pembrolizumab, when combined with chemotherapy, doubles survival in patients with non-squamous non-small cell lung cancer (NSNSCLC) lacking genetic changes in the EGFR or ALK genes, when compared to...

The FDA granted approval to pembrolizumab (Keytruda, Merck), a checkpoint immunotherapy that targets the PD - 1 pathway, to treat advanced, recurrent cancer of the stomach and gastroesophageal junction.

Pembrolizumab is the sixth immunotherapy (and fifth anti-PD-1 / PD - L1 checkpoint inhibitor) to be approved for bladder cancer patients.

Pembrolizumab is the third immunotherapy (and first checkpoint inhibitor) to be approved for patients with stomach and gastroesophageal cancer.

On October 2, 2015, the FDA approved the immunotherapy drug pembrolizumab (Keytruda ®), made by Merck, as second - line treatment for patients with lung cancer, the leading cause of cancer - related death in the U.S. and the world.

The FDA granted approval to pembrolizumab (Keytruda, Merck), a checkpoint immunotherapy that targets the PD - 1 pathway, as a second - line treatment for advanced bladder cancer.

Aside from atezolizumab, immunotherapies in this class include avelumab (Bavencio); pembrolizumab (Keytruda); and nivolumab (Opdivo).

The FDA also approved another immunotherapy drug, Merck's pembrolizumab, known commercially as Keytruda, for patients with tumors harboring this defect regardless of cancer type.

Most recently, pembrolizumab (Keytruda ®), an anti-PD-1 checkpoint immunotherapy, was approved for patients with advanced, relapsed stomach cancer that expresses PD - L1.

The immunotherapy drugs are ipilimumab (Yervoy ®), pembrolizumab (Keytruda ®), nivolumab (Opdivo ®), and talimogene laherparepvec (T - VEC, Imlygic ™).

Ramuacirumab (CYRAMZA ®), an anti-VEGFR2 targeted antibody, is also appproved for esophageal cancer patients, while pembrolizumab (Keytruda ®), an anti-PD-1 checkpoint immunotherapy, is approved for patients with advanced cancers of the gastroesophageal junction that express PD - L1.

But the disease did recur in the other 2 patients with stage IV melanoma, though both responded to further treatment using the immunotherapy drug pembrolizumab.

The study consists of two phases and involves two promising immunotherapy drugs: pembrolizumab and talimogene laherparepvec (T - VEC).

Those who do not respond to pembrolizumab immunotherapy lack a certain type of immune cell inside their tumor lesions.

May 29, 2015 Pembrolizumab shows real promise against head and neck cancer Immunotherapy with the anti-PD-1 antibody pembrolizumab (Keytruda ®) was effective in one out of four patients with recurrent or metastatic head and neck cancer, according to results presented at the 2015 meeting of the American Society for Clinical OncPembrolizumab shows real promise against head and neck cancer Immunotherapy with the anti-PD-1 antibody pembrolizumab (Keytruda ®) was effective in one out of four patients with recurrent or metastatic head and neck cancer, according to results presented at the 2015 meeting of the American Society for Clinical Oncpembrolizumab (Keytruda ®) was effective in one out of four patients with recurrent or metastatic head and neck cancer, according to results presented at the 2015 meeting of the American Society for Clinical Oncology (ASCO).

Tags: checkpoint inhibitors, Clinical Research, immunotherapy, Lung Cancer, McGarry Houghton, Ovarian Cancer, pembrolizumab, Philip D Greenberg, solid tumors, T cell, t cell therapy, Transplant and immunotherapy, Lung Cancer, McGarry Houghton, Ovarian Cancer, pembrolizumab, Philip D Greenberg, solid tumors, T cell, t cell therapy, Transplant and ImmunotherapyImmunotherapy

In the first phase of MasterKey, T - VEC was injected into the tumors of 21 patients with advanced melanoma, followed by pembrolizumab immunotherapy.

The drug he was given, pembrolizumab (brand name Keytruda), is part of a rapidly growing class of drugs called immunotherapy, which uses the body's immune system to fight the cancer.